Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon.

"Declaration of competing interest The authors have no competing interests to declare."

"Funding The pharmacovigilance study on AQ, SP, and SP-AQ conducted from 2004-2006 in Yaounde was supported by a subgrant to WFM (ITDC VG 34), from the Gates Malaria Partnership at the London School of Hygiene and Tropical Medicine, which received support from the Bill and Melinda Gates Foundation, USA. Additional financial support for equipment was provided by the International Atomic Energy, Agency grant number RAF6/0/25, Vienna. The IPP study conducted in 2014 in Yaounde was supported financially by the National Institutes of Health Research Training Grant #R25 TW009345 awarded to the Northern Pacific Global Health Fellows Program by the Fogarty International Center/National Institutes for Health, USA and GID Training Grant-D43TW009074 FIC/NIH. The pharmacovigilance study on artesunate-amodiaquine and AL carried out from 2019 to 2020 in Yaounde was funded in whole by the Wellcome Trust (grant # 107741/A/15/Z) and the UK Foreign, Commonwealth and Development Office, with support from the Developing Excellence in Leadership, Training and Science in Africa (DELTAS Africa) program. This study was also funded by the 10.13039/100000002National Institutes of Health (NIH), USA (grant # U19AI089672). For the purpose of open access, the author has applied a CC BY public copyright license to any author-accepted manuscript version arising from this submission."